| Name | Title | Contact Details |
|---|---|---|
Alena Hoppner |
Director, Revenue Accounting - NA | Profile |
JoAnne Dias |
Director Of Purchasing | Profile |
Ugandhar chapalamadugu |
Chief Executive Officer/ Chief Technical Officer/Chief Product Officer | Profile |
Kim Smart |
VP HR Business Unit Functions and Org Effectiveness | Profile |
Meagen Mahowald |
Director of Sales Training | Profile |
Ganix is a Las Vegas, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Innoviva is a healthcare royalty and asset management company that focuses on maximizing the long-term potential of its royalty portfolio and fueling innovation in areas of significant, often overlooked unmet medical need.
DMS Provides Mobile, Interim, and Fixed-Site Diagnostic Imaging Services and Medical Equipment Sales, Service, Parts, Rentals.
Mérieux NutriSciences is a service company headquartered in Chicago.
Advanced Cell Diagnostics, Inc. (ACD) is a leader in the emerging field of molecular pathology, developing cell- and tissue-based diagnostic tests for personalized medicine. Based in the heart of Silicon Valley, ACD was founded and managed by experienced entrepreneurs in the life science industry. ACD’s products and services are based on its proprietary RNAscope® Technology, the first multiplex fluorescent and chromogenic in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single molecule sensitivity. In addition to its ongoing efforts to develop proprietary diagnostic tests for cancer management, ACD also establishes partnerships with pharmaceutical and biotechnology companies to validate biomarkers for targeted therapeutic development. These internal and external efforts will continue to position ACD as a leader in molecular diagnostics and companion diagnostics. The company’s technology overcomes critical hurdles in the identification and validation of biomarkers for companion diagnostics. ACD’s RNAscope® platform provides a new way of localizing and measuring RNA in situ with exceptional levels of sensitivity, specificity, and the ability to multiplex. Turnaround time for a new assay is reduced to three weeks. These advantages make the technology a powerful tool to address the issue of patient and disease heterogeneity, thus shortening the path to personalized medicine.